Skip to main content
Equibles

CGEN · Compugen Ltd

Track CGEN — free

Use CGEN with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research CGEN.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$2.31 +0.00 (+0.00%) At close · Oct 5
Rebalance outlook locked
Market Cap
$223.34M
Shares
94.72M
Volume · Oct 5 198.87K Avg daily vol (3M) 251.13K

Price & Indicators

Drag to pan · scroll to zoom
Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.31 Open$2.34 Day$2.31–2.38 52W close$1.47–3.10 Avg vol 30d225K Short int2.4M · 2.5% float · 12.0d Short vol72% Last earningsAug 3, 2026 DataJan 2020–Oct 2026

Up next

Next earnings call
Oct 27, 2026 Est · unconfirmed · in 3 wks
Q4 2025 earnings call transcript
call held Mar 2, 2026

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
+161.1%
Year over year
Operating margin
43.1%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
+4.8%
Year over year · more shares
Price change (1Y)
+31.3%
Trailing year
Short interest
2.5%
Latest settlement · 12.0 days to cover
View all 115 metrics

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Neutral Momentum Weak Sentiment Neutral Fundamentals Excellent Quant / Vol High
Market backdrop VIX 15.3 · calm Equity put/call 0.59
Technical
price trend
Neutral
50 / 200-day cross No cross
Price vs 200-day avg +2%
above
Price vs 50-day avg −6%
below
RSI (14) 40
neutral
MACD trend Negative
52-week position 52%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Weak
1-month return −10%
trailing
6-month return −16%
trailing
YTD return +51%
this year
Relative strength −28%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Accumulating
+5% holders QoQ · +15 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.50% of float · ▲ +0.8% MoM · 12.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
83 holders — near 3-yr high, broad support
Squeeze score 57
elevated · 0–100
Fundamentals
Excellent
Revenue growth +161%
Y/Y
Gross margin 87%
expanding
EPS growth +338%
Y/Y
Free cash flow $31.3M
Quant / Vol
risk profile
High
Volatility 69%
annualized · 1-yr
Max drawdown −37%
past year
ATR 4.0%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Neutral
2 · 4 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+2% Bullish
Price vs 50-day avg
−6% Bearish
RSI (14)
40 Neutral
MACD trend
Negative Bearish
52-week position
52% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 50d above 200d
Institutional flow Accumulating
+5% holders QoQ · +15 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Rising
2.50% of float · ▲ +0.8% MoM · 12.0 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
83 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $2 · 52% Range high $3
vs 200-day avg +2% vs 50-day avg -6%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
CGEN
Compugen Ltd
this stock
$223.34M +51.0% +161.1% — 2.5%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $133.37B +11.3% +46.2% 30.7 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
 $81.13B -4.8% +20.8% 19.5 2.5%
MRNA
Moderna, Inc.
 $79.40B +544.3% +4.3% — 8.2%
CSLLY
Csl Ltd
 $61.25B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
83
% held
15.2%
Net QoQ
+71.5K sh
Top holder
SILVERARC CAPITAL MANAGEM…
Held Float
View
Held by Funds
Fund positions
2
View
Short & Settlement
Short Interest Rising
Shares short
2.4M
Days to cover
12.0d
Change
+17.7K sh
View
Short Volume
Short vol %
72%
As of
Oct 5, 2026
Short Total
View
Fails to Deliver
FTD shares
6.9K
Value
$17.7K
As of
Sep 9, 2026
View
Off-Exchange
Off-exchange %
44.6%
Week of
Aug 31, 2026
Off-exch Lit
View
Financials
Financials
Revenue (FY)
$72.8M
Net income (FY)
$35.3M
EPS diluted
$0.38
View
Filings
SEC Filings
Latest
6-K
Filed
Sep 10, 2026
This year
9
View
Proposed Sales
Value
$11.7K
Shares
4.0K
Filed
Apr 27, 2026
View
Exempt Offerings
Offering
$20.0M
Filed
Nov 22, 2021
View
Earnings & Events
Webcasts
Last webcast
Oct 5, 2026
View
Investor Relations
Latest news
Compugen to Host Virtual KOL Even…
Published
Sep 22, 2026
View

Performance

5D 20D 120D MTD YTD
CGEN -2.9% -9.8% -16.3% -2.9% +51.0%
SPY -0.2% -0.5% +12.2% +0.9% +12.9%
vs SPY -2.7% -9.3% -28.5% -3.9% +38.1%
Key facts CIK 1119774 CUSIP M25722105 13F (30d) 2 filings 2 filers Visit website Investor relations